Efficacy observation of icotinib hydrochloride tablets in the targeted treatment of advanced non-small cell lung cancer
Objective To investigate the clinical efficacy of icotinib hydrochloride tablets in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 50 cases of patients with non-small cell lung cancer (NSCLC) were enrolled in Pan'an County People's hospital from December 2014 to April 2014, and all the patients were treated with icotinib hydrochloride tablets and targeted treatment. The clinical effect and adverse reactions were analyzed. Results There were 10 patients with complete remission after treatment, 22 patients were partial remission, 14 patients were in stable condition and 6 patients with disease progression. After statistical analysis, the objective effective rate was 44%, and the disease control rate was 88%. In the clinical efficacy analysis, the curative effect of the patients was found to be related to the age, smoking history and ECOG score of the patients (P<0.05). There were rash, skin itching, diarrhea, stomach discomfort and liver injury, mainly for the first degree of adverse reactions, accounting for 13%. Conclusion The application of icotinib hydrochloride tablets in the targeted treatment of advanced non-small cell lung cancer (NSCLC) has a very good clinical effect.
NETL
NSTL
万方数据
维普
